Acasti announces first quarter 2024 financial results and business highlights

Princeton, n.j, aug. 11, 2023 (globe newswire) -- acasti pharma inc. (nasdaq: acst) (acasti or the company), a late-stage, biopharma company advancing gtx-104, its novel formulation of nimodipine that addresses the high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (asah), today announced financial results and business highlights for the quarter ended june 30, 2023.
ACST Ratings Summary
ACST Quant Ranking